ReviewClinical and experimental medicine2026
A review of deep learning-based multimodal data integration of lung cancer.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This is a narrative review that provides a perspective on the recent advances in deep learning (DL)-driven multimodal data integration for lung cancer. Lung cancer remains the most prevalent malignancy and the leading cause of cancer-related mortality worldwide. Despite growing awareness and therapeutic innovations, the majority of cases are diagnosed at advanced stages, resulting in persistently poor survival rates. In recent years, artificial intelligence (AI) has demonstrated transformative potential in oncology research, particularly through the integration of heterogeneous biomedical data modalities. The fusion of radiological imaging, histopathological slides, genomic and transcriptomic profiles, and electronic health records has consistently outperformed unimodal approaches by capturing complementary biological and clinical information. DL-based multimodal integration frameworks have shown promise in improving diagnostic accuracy, stratifying patients according to therapeutic response, and predicting long-term prognosis, thereby contributing to precision oncology. By leveraging the synergistic strengths of diverse data sources, multimodal AI models can enable more accurate and individualized strategies for diagnosis, treatment planning, and longitudinal disease monitoring, ultimately improving clinical outcomes for patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.